Press Release

Verve Therapeutics to Present at the Piper Sandler Annual Virtual Healthcare Conference

CAMBRIDGE, Mass. — November 23, 2020 — Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place November 30-December 3, 2020.

Dr. Kathiresan will present a corporate overview on Verve’s strategy to develop one-time gene editing medicines that transform the treatment of coronary heart disease. He will discuss the company’s preclinical progress in nonhuman primates using base editing to safely and precisely turn off a gene in the liver to lower LDL cholesterol and triglyceride blood levels. He will also highlight upcoming development milestones and timelines. The presentation will be pre-recorded and available to registered attendees to access on demand throughout the conference.

In addition, Dr. Kathiresan will be available for one-on-one investor meetings on Monday, November 30, 2020. He will also participate in a panel discussion on cardiovascular gene editing and gene therapy on Wednesday, December 2, 2020, at 11:00 a.m. ET.


About Verve Therapeutics

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. The company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. Verve is developing medicines, administered once in life, to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels and thereby treat coronary heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, Verve is backed by a top-tier syndicate of investors, including GV (formerly Google Ventures), ARCH Venture Partners, F-Prime Capital, Biomatics Capital, Wellington Management, Casdin Capital, and Partners Innovation Fund. Verve is headquartered in Cambridge, Massachusetts. For more information, visit 

Media Contact

Gina Nugent, 617-460-3579
Ten Bridge Communications